We’re experiencing issues for some mobile devices with our ARTG dataset filter function. We apologise for any inconvenience while we work to fix this.
SPIKEVAX (Moderna Australia Pty Ltd)
Product name
SPIKEVAX
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
132 (255 working days)
Active ingredients
SARS-CoV-2 spike protein (mRNA) LP.8.1
Registration type
NCE/NBE
Indication
SPIKEVAX LP.8.1 (SARS-CoV-2 spike protein (mRNA) LP.8.1) COVID-19 Vaccine is indicated for:
Active immunisation to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 in individuals 12 years of age and older.
The use of this vaccine should be in accordance with official recommendations.